Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache

Completed

Conditions studied: Migraine

In brief

The primary objective is to determine whether inflammatory markers, such as C-Reactive Protein (CRP), Calcitonin Gene-Related Peptide (CGRP), Vasoactive Intestinal Polypeptide (VIP), or Substance P (SP) are reduced in patients having a migraine headache when treated with Imitrex or Treximet. The secondary objective is to determine the effects of Imitrex and Treximet on C-Reactive Protein (CRP) in patients with active migraine headaches.

Key facts

Study ID

NCT01916395

Run by

Gary E. Ruoff, M.D.

People needed

30

Starts

2009-12-01

Expected to finish

2011-07-01

Last updated by the study team

2013-08-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subject must sign an informed consent
• Males and females 18 - 65 years of age
• Have episodic migraine headaches
• Patients to satisfy the diagnosis of migraine headaches with aura, without aura or mixed
• Must be able to differentiate migraine headaches from other headaches
• Diagnosis of migraines for at least 6 months

You may not qualify if…

• Any medical condition, in the opinion of the investigator, that would make the subject unsuitable for enrollment
• Basilar or hemiplegic migraine headaches
• Pregnant woman or a nursing mother
• History (within 1 year) or current evidence of grug or alcohol abuse
• More than 15 migraine headaches per month
• Chronic daily headache
• Chronic use of NonSteroidalAntiInglammatoryDrugs
• Current participation in a research study or within the last 30 days

Where it is running

• Westside Family Medical Center, PC — Kalamazoo, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.